Trevena Inc. (NASDAQ:TRVN)’s share price dropped 3.6% on Monday . The stock traded as low as $6.31 and last traded at $6.44, with a volume of 277,106 shares traded. The stock had previously closed at $6.68.

TRVN has been the topic of several research reports. TheStreet downgraded shares of Trevena from a “hold” rating to a “sell” rating in a research note on Friday, June 17th. FBR & Co initiated coverage on shares of Trevena in a research note on Tuesday, March 29th. They issued an “outperform” rating and a $16.00 price target on the stock. Cowen and Company reissued a “buy” rating on shares of Trevena in a research note on Thursday, June 2nd. Zacks Investment Research raised shares of Trevena from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Finally, Wedbush reissued a “positive” rating on shares of Trevena in a research note on Thursday, April 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.70.

The stock’s market cap is $339.65 million. The company has a 50-day moving average price of $6.65 and a 200 day moving average price of $7.60.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.03. On average, analysts predict that Trevena Inc. will post ($1.29) EPS for the current fiscal year.

In other Trevena news, CEO Maxine Gowen purchased 22,084 shares of the business’s stock in a transaction dated Friday, May 27th. The stock was bought at an average cost of $7.12 per share, for a total transaction of $157,238.08. Following the completion of the acquisition, the chief executive officer now directly owns 279,025 shares in the company, valued at $1,986,658. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Several hedge funds have recently added to or reduced their stakes in TRVN. California State Teachers Retirement System boosted its stake in Trevena by 77.9% in the fourth quarter. California State Teachers Retirement System now owns 103,238 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 45,212 shares in the last quarter. Marshall Wace LLP purchased a new stake in Trevena during the fourth quarter worth about $1,929,000. Finally, Jennison Associates LLC boosted its stake in Trevena by 0.3% in the fourth quarter. Jennison Associates LLC now owns 702,341 shares of the biopharmaceutical company’s stock worth $7,375,000 after buying an additional 2,341 shares in the last quarter.

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.